Protalix BioTherapeutics (PLX) Other Non-Current Liabilities (2011 - 2021)

Protalix BioTherapeutics' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $38000.0 for Q2 2021.

• On a quarterly basis, Other Non-Current Liabilities fell 69.35% year-over-year to $38000.0 in Q2 2021; TTM through Jun 2021 was $38000.0, a 69.35% decrease from a year earlier, with the FY2020 full-year figure at $51000.0, down 89.98% from the prior year.
• Other Non-Current Liabilities grew to $38000.0 in Q2 2021 per PLX's latest filing, from $26000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $6.2 million in Q3 2018 and bottomed at $26000.0 in Q1 2021.
• The 5-year median for Other Non-Current Liabilities is $5.1 million (2017), against an average of $2.9 million.
• Across the five-year window, Other Non-Current Liabilities rose 17.44% in 2017 and tumbled 99.14% in 2020, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $5.1 million in 2017, then increased by 4.77% to $5.3 million in 2018, then sank by 90.38% to $509000.0 in 2019, then sank by 89.98% to $51000.0 in 2020, then decreased by 25.49% to $38000.0 in 2021.
• Per Business Quant, the three latest PLX Other Non-Current Liabilities figures stand at $38000.0 (Q2 2021), $26000.0 (Q1 2021), and $51000.0 (Q4 2020).